| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA875369 | P | Dissociation constant (pKa) | 48 | small-molecule physicochemical format | Scientific Literature | |||
| 2. | ALA638474 | P | Partition coefficient (logD7.2) | 47 | small-molecule physicochemical format | Scientific Literature | |||
| 3. | ALA636802 | P | Partition coefficient (logP) | 50 | assay format | Scientific Literature | |||
| 4. | ALA650770 | F | Inhibitory activity on germination of Bacillus subtilis PCI219 spores was determined. | Bacillus subtilis | 46 | organism-based format | Scientific Literature | ||
| 5. | ALA650437 | F | Inhibition of Bacillus subtilis PCI219 spore germination, expressed as log 1/I50 | Bacillus subtilis | 47 | organism-based format | Scientific Literature | ||
| 6. | ALA1794339 | F | PUBCHEM_BIOASSAY: qHTS assay for small molecule agonists of vitamin D receptor signaling. (Class of assay: confirmatory) | 245 | assay format | PubChem BioAssays | |||
| 7. | ALA1809747 | F | Antileishmanial activity against Leishmania amazonensis MHOM/IFLA/BR/67/PH8 promastigotes after 72 hrs by cell counting using Neubauer chamber | Leishmania amazonensis | 11 | organism-based format | Scientific Literature | ||
| 8. | ALA1809748 | F | Antileishmanial activity against Leishmania chagasi MCAN/BR/99/JP15 promastigotes after 72 hrs by cell counting using Neubauer chamber | Leishmania chagasi | 11 | organism-based format | Scientific Literature | ||
| 9. | ALA1909163 | B | DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) | Cavia porcellus | 871 | tissue-based format | DrugMatrix | ||
| 10. | ALA1909164 | B | DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) | 871 | cell membrane format | DrugMatrix | |||
| 11. | ALA1909165 | B | DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) | Oryctolagus cuniculus | 871 | tissue-based format | DrugMatrix | ||
| 12. | ALA1909166 | B | DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) | 871 | cell membrane format | DrugMatrix | |||
| 13. | ALA1909167 | B | DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) | 871 | cell membrane format | DrugMatrix | |||
| 14. | ALA1909168 | B | DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) | 871 | cell membrane format | DrugMatrix | |||
| 15. | ALA1909169 | B | DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) | 871 | cell-based format | DrugMatrix | |||
| 16. | ALA1909170 | B | DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) | 871 | cell membrane format | DrugMatrix | |||
| 17. | ALA1909171 | B | DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) | 871 | cell membrane format | DrugMatrix | |||
| 18. | ALA1909172 | B | DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) | 871 | cell membrane format | DrugMatrix | |||
| 19. | ALA1909173 | B | DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) | 871 | cell membrane format | DrugMatrix | |||
| 20. | ALA1909174 | B | DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) | 871 | cell membrane format | DrugMatrix |
The page will load shortly, Thanks for your patience!